Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2535 December 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Budesonide - Cap 3 mg Controlled Rel	ease	
or History of severe psychiatric or History of major mental illne relapse is considered to be in Relapse during pregnancy (see the constant of	significant risk of fracture nent with conventional corticosteroid therapy problems associated with corticosteroid treatment as (such as bipolar affective disorder) where the risk high where conventional corticosteroids are considered to	
Initial application — collagenous and lymphocy Applications from any relevant practitioner. Approx Prerequisites(tick box where appropriate)  Patient has a diagnosis of microscopic collaboration.	ytic colitis (microscopic colitis) vals valid without further renewal unless notified.  colitis (collagenous or lymphocytic colitis) by colonosc	opy with biopsies
Initial application — gut Graft versus Host dise Applications from any relevant practitioner. Approx Prerequisites(tick box where appropriate)  Patient has a gut Graft versus Host disea Note: Indication marked with * is an unapproved in the second	vals valid for 6 months.  ase following allogenic bone marrow transplantation*	

Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA2535 December 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Budesonide - Cap 3 mg Controlled Rel	ease - continued	
or History of severe psychiatric or History of major mental illne	significant risk of fracture nent with conventional corticosteroid therapy problems associated with corticosteroid treatment ss (such as bipolar affective disorder) where the risk	of conventional corticosteroid treatment causing
or Palance during programmy		he centraindicated)
or	where conventional corticosteroids are considered to	
Adolescents with poor linear	growth (where conventional corticosteroid use may I	imit further growth)
Note: Indication marked with * is an unapproved in	ndication.	
Renewal — gut Graft versus Host disease  Current approval Number (if known):  Applications from any relevant practitioner. Approver Prerequisites (tick box where appropriate)  The treatment remains appropriate and to the second	vals valid for 6 months.	
Renewal — non-cirrhotic autoimmune hepatitis	3	
Current approval Number (if known):		
Applications from any relevant practitioner. Approx <b>Prerequisites</b> (tick box where appropriate)	vals valid for 6 months.	
The treatment remains appropriate and t	he patient is benefiting from treatment	